Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG(TM) Catheter

Stock Information for PharmaCyte Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PharmaCyte Biotech Inc.

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.